Last reviewed · How we verify
Lenvatinib, sintilimab plus TACE
This combination uses lenvatinib (a multi-kinase inhibitor) and sintilimab (a PD-1 inhibitor) together with TACE (transarterial chemoembolization) to target hepatocellular carcinoma through anti-angiogenic, immunostimulatory, and locoregional chemotherapy mechanisms.
This combination uses lenvatinib (a multi-kinase inhibitor) and sintilimab (a PD-1 inhibitor) together with TACE (transarterial chemoembolization) to target hepatocellular carcinoma through anti-angiogenic, immunostimulatory, and locoregional chemotherapy mechanisms. Used for Advanced or unresectable hepatocellular carcinoma.
At a glance
| Generic name | Lenvatinib, sintilimab plus TACE |
|---|---|
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University |
| Drug class | Multi-kinase inhibitor + PD-1 inhibitor + locoregional chemotherapy |
| Target | FGFR, VEGFR, RET, KIT (lenvatinib); PD-1 (sintilimab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenvatinib inhibits multiple receptor tyrosine kinases (FGFR, VEGFR, RET, KIT) to suppress tumor angiogenesis and growth. Sintilimab is a PD-1 checkpoint inhibitor that restores anti-tumor T-cell immunity. TACE delivers chemotherapy directly to the tumor while occluding its blood supply. The combination aims to synergize anti-angiogenic, immunologic, and locoregional cytotoxic effects in advanced hepatocellular carcinoma.
Approved indications
- Advanced or unresectable hepatocellular carcinoma
Common side effects
- Hypertension
- Proteinuria
- Fatigue
- Diarrhea
- Immune-related adverse events (from sintilimab)
- Post-embolization syndrome (from TACE)
Key clinical trials
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk (PHASE2)
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC (PHASE2)
- TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma (NA)
- Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT (PHASE2)
- Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
- Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
- Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Survival Analysis: TACE vs. Combination Therapy in HCC
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |